Savient Pharmaceuticals Receives Complete Response Letter from U.S. Food and Drug Administration for KRYSTEXXA(TM) Aug 3, 2009
Savient to Host Conference Call on Monday, August 3, 2009 at 8:00am. EAST BRUNSWICK, N.J., Aug. 2 /PRNewswire-FirstCall/ -- Savient Pharmaceuticals, Inc. (Nasdaq: ) today announced that the Company has received a complete response letter from the U.S. Food and Drug Administration (FDA) stating that the FDA can not at this time approve the Company's Biologics License Application (BLA) for KRYSTEXXA(TM) (pegloticase) as a treatment for chronic gout in patients refractory to conventional therapy. (PR Newswire)
Population Study of 1311 C/T polymorphism of Glucose 6 Phosphate Dehydrogenase gene in Pakistan- an analysis of 715 X-chromosomes Jul 30, 2009
The present study will help in understanding genetic basis of G6PD deficiency in Pakistani population and in developing ancestral links of its various ethnic groups. The complete article is available as a. (BioMed Central)
An optimised system for refolding of human glucose 6-phosphate dehydrogenase Mar 12, 2009
Accordingly haemolytic disease is a major consequence of G6PD deficiency mutations in man, and many severe disease phenotypes are attributed to G6PD folding problems. Therefore, a robust refolding method with high recovery yield and reproducibility is of particular importance to study those clinical mutant enzymes as well as to shed light generally on the refolding process of large multi-domain proteins. (BioMed Central)
Scientists begin to decode the history of human evolution Feb 14, 2009
So great was their value that they became widespread, even though they can cause problems of their own sickle cell anemia, thalassemia and G6PD deficiency, diseases most prevalent in places where malaria was a scourge. Matching Skin Tone to Sunlight. (Atlanta Journal-Constitution -- Health)